Medivir AB (publ)
MVRBF
Get informed when a big investor buys or sells
+ FollowMarket Cap$45.7M
Close$
Share Statistics
| Market cap | $45.70 Million |
|---|---|
| Enterprise Value | $62.88 Million |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $-1.59 |
| Beta | 0.36 |
| Outstanding Shares | 55,736,000 |
Return
| Return on Equity | -45.99% |
|---|---|
| Return on Assets | -37.86% |
| Return on Invested Capital | -33.32% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 0.27 |
| Enterprise Value to Revenue | 14.26 |
| Enterprise Value to EBIT | -0.92 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.38 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Medivir AB (publ)
10 employees
CEO: Jens Lindberg Established in 1987 and headquartered in Huddinge, Sweden, Medivir AB (publ) is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products. Its primary therapeutic area is oncology,...